PROM1 and neoplasm: The combined delivery of SLM- and gefitinib-NPs was more effective in eliminating CD133+ CSCs and reducing tumor volume, compared to SLM/gefitinib-loaded NPs, or individually delivered SLM-NPs and gefitinib-NPs.